English

Audentes Therapeutics, Inc.

EDGAR

BOLD Current report (8-K) · filed 2019-12-03

134 filing records in this dataset, filed from 2016-01-04 to 2019-12-03. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Cash and cash equivalents: 63.6 million USD 2019-09-30 Source
Exact value

63600000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 45.7 million shares 2019-09-30 Source
Exact value

45740575 shares

Reported share-count change

22.13% · 8.29 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

37453129 shares · 2018-09-30· Source
45740575 shares · 2019-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-175 million USD

2018-10-01 – 2019-09-30

Exact inputs and evidence

Net income: -35592000 USD · 2018-10-01 – 2018-12-31 Source
Net income: -49391000 USD · 2019-01-01 – 2019-03-31 Source
Net income: -44764000 USD · 2019-04-01 – 2019-06-30 Source
Net income: -45741000 USD · 2019-07-01 – 2019-09-30 Source

Operating cash flow

-147 million USD

2018-10-01 – 2019-09-30

Exact inputs and evidence

Operating cash flow: -107978000 USD · 2018-01-01 – 2018-12-31 Source
Operating cash flow: -79495000 USD · 2018-01-01 – 2018-09-30 Source
Operating cash flow: -42220000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -83044000 USD · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -42220000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -118917000 USD · 2019-01-01 – 2019-09-30 Source
Operating cash flow: -83044000 USD · 2019-01-01 – 2019-06-30 Source

Capital expenditure

13.6 million USD

2018-10-01 – 2019-09-30

Exact inputs and evidence

Capital expenditure: 11609000 USD · 2018-01-01 – 2018-12-31 Source
Capital expenditure: 8074000 USD · 2018-01-01 – 2018-09-30 Source
Capital expenditure: 1288000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 5641000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 1288000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 10017000 USD · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 5641000 USD · 2019-01-01 – 2019-06-30 Source

Free cash flow

-161 million USD

2018-10-01 – 2019-09-30

Exact inputs and evidence

Operating cash flow: -107978000 USD · 2018-01-01 – 2018-12-31 Source
Operating cash flow: -79495000 USD · 2018-01-01 – 2018-09-30 Source
Operating cash flow: -42220000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -83044000 USD · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -42220000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -118917000 USD · 2019-01-01 – 2019-09-30 Source
Operating cash flow: -83044000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 11609000 USD · 2018-01-01 – 2018-12-31 Source
Capital expenditure: 8074000 USD · 2018-01-01 – 2018-09-30 Source
Capital expenditure: 1288000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 5641000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 1288000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 10017000 USD · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 5641000 USD · 2019-01-01 – 2019-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2019-12-03.

Financial data available through: 2018-12-31.

Coverage by financial measure

revenue: No compatible figures in this window
Operating income: 5 of 11 periods available· newest 2018-12-31
Net income: 5 of 11 periods available· newest 2018-12-31
Operating cash flow: 5 of 11 periods available· newest 2018-12-31
Capital expenditure: 5 of 11 periods available· newest 2018-12-31
Total assets: 4 of 11 periods available· newest 2018-12-31
Total liabilities: 4 of 11 periods available· newest 2018-12-31
Current assets: 4 of 11 periods available· newest 2018-12-31
Current liabilities: 4 of 11 periods available· newest 2018-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2018-12-31
long term debt: No compatible figures in this window
Shares outstanding: 4 of 11 periods available· newest 2018-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 38.58 million

Prior period

−USD 90.24 million

2017-01-01 – 2017-12-31
Current period

−USD 128.82 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

-128821000 − -90238000 = -38583000 USD

-90238000 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
-128821000 USD · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Audentes Therapeutics, Inc. · 2018-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Year-over-year change in Net income: -38583000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -128821000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#176116 Filing: 000156459019005838 Input fundies:NetIncome: -90238000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#176271 Filing: 000156459019005838
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 23.41 million

Prior period

−USD 84.57 million

2017-01-01 – 2017-12-31
Current period

−USD 107.98 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

-107978000 − -84565000 = -23413000 USD

-84565000 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
-107978000 USD · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Audentes Therapeutics, Inc. · 2018-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Year-over-year change in Operating cash flow: -23413000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -107978000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#203929 Filing: 000156459019005838 Input fundies:OperatingCashFlow: -84565000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#204142 Filing: 000156459019005838
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+53.7%

Prior period

USD 7.55 million

2017-01-01 – 2017-12-31
Current period

USD 11.61 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

11609000 − 7551000 = 4058000 USD

7551000 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
11609000 USD · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Audentes Therapeutics, Inc. · 2018-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Year-over-year change in Capital expenditure: 4058000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 11609000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#204566 Filing: 000156459019005838 Input fundies:CapitalExpenditure: 7551000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#204777 Filing: 000156459019005838
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.

Values and sources

Revenue values and source evidence
Period	Series	Value	Source evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value	Source evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	−USD 10.82 million Exact value Exact value: -10819000 USD 2014-01-01 – 2014-12-31: -10819000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Audentes Therapeutics, Inc. · 2014-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Net Income: -10819000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10819000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459017004021/bold-20161231.xml#159191 Filing: 000156459017004021 The citation records this snapshot. The page link may show a newer release later.	−USD 8.07 million Exact value Exact value: -8069000 USD 2014-01-01 – 2014-12-31: -8069000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Audentes Therapeutics, Inc. · 2014-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Operating Cash Flow: -8069000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8069000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459017004021/bold-20161231.xml#191753 Filing: 000156459017004021 The citation records this snapshot. The page link may show a newer release later.	USD 125,000 Exact value Exact value: 125000 USD 2014-01-01 – 2014-12-31: 125000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Audentes Therapeutics, Inc. · 2014-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Capital Expenditure: 125000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 125000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459017004021/bold-20161231.xml#193574 Filing: 000156459017004021 The citation records this snapshot. The page link may show a newer release later.	−USD 8.19 million Calculation and evidence -8069000 − 125000 USD Exact free cash flow: -8194000 USD 2014-01-01 – 2014-12-31: -8069000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 125000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Audentes Therapeutics, Inc. · 2014-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Free cash flow: -8194000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8069000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459017004021/bold-20161231.xml#191753 Filing: 000156459017004021 Input fundies:CapitalExpenditure: 125000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459017004021/bold-20161231.xml#193574 Filing: 000156459017004021 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 26.46 million Exact value Exact value: -26458000 USD 2015-01-01 – 2015-12-31: -26458000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Audentes Therapeutics, Inc. · 2015-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Net Income: -26458000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -26458000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459018005154/bold-20171231.xml#150883 Filing: 000156459018005154 The citation records this snapshot. The page link may show a newer release later.	−USD 27.52 million Exact value Exact value: -27515000 USD 2015-01-01 – 2015-12-31: -27515000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Audentes Therapeutics, Inc. · 2015-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Operating Cash Flow: -27515000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -27515000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459018005154/bold-20171231.xml#182872 Filing: 000156459018005154 The citation records this snapshot. The page link may show a newer release later.	USD 1.69 million Exact value Exact value: 1686000 USD 2015-01-01 – 2015-12-31: 1686000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Audentes Therapeutics, Inc. · 2015-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Capital Expenditure: 1686000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1686000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459018005154/bold-20171231.xml#184072 Filing: 000156459018005154 The citation records this snapshot. The page link may show a newer release later.	−USD 29.2 million Calculation and evidence -27515000 − 1686000 USD Exact free cash flow: -29201000 USD 2015-01-01 – 2015-12-31: -27515000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 1686000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Audentes Therapeutics, Inc. · 2015-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Free cash flow: -29201000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -27515000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459018005154/bold-20171231.xml#182872 Filing: 000156459018005154 Input fundies:CapitalExpenditure: 1686000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459018005154/bold-20171231.xml#184072 Filing: 000156459018005154 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 59.67 million Exact value Exact value: -59668000 USD 2016-01-01 – 2016-12-31: -59668000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Audentes Therapeutics, Inc. · 2016-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Net Income: -59668000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -59668000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#176425 Filing: 000156459019005838 The citation records this snapshot. The page link may show a newer release later.	−USD 48.93 million Exact value Exact value: -48926000 USD 2016-01-01 – 2016-12-31: -48926000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Audentes Therapeutics, Inc. · 2016-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Operating Cash Flow: -48926000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -48926000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#204354 Filing: 000156459019005838 The citation records this snapshot. The page link may show a newer release later.	USD 16.65 million Exact value Exact value: 16651000 USD 2016-01-01 – 2016-12-31: 16651000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Audentes Therapeutics, Inc. · 2016-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Capital Expenditure: 16651000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 16651000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#204987 Filing: 000156459019005838 The citation records this snapshot. The page link may show a newer release later.	−USD 65.58 million Calculation and evidence -48926000 − 16651000 USD Exact free cash flow: -65577000 USD 2016-01-01 – 2016-12-31: -48926000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 16651000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Audentes Therapeutics, Inc. · 2016-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Free cash flow: -65577000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -48926000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#204354 Filing: 000156459019005838 Input fundies:CapitalExpenditure: 16651000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#204987 Filing: 000156459019005838 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 90.24 million Exact value Exact value: -90238000 USD 2017-01-01 – 2017-12-31: -90238000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Audentes Therapeutics, Inc. · 2017-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Net Income: -90238000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -90238000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#176271 Filing: 000156459019005838 The citation records this snapshot. The page link may show a newer release later.	−USD 84.57 million Exact value Exact value: -84565000 USD 2017-01-01 – 2017-12-31: -84565000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Audentes Therapeutics, Inc. · 2017-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Operating Cash Flow: -84565000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -84565000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#204142 Filing: 000156459019005838 The citation records this snapshot. The page link may show a newer release later.	USD 7.55 million Exact value Exact value: 7551000 USD 2017-01-01 – 2017-12-31: 7551000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Audentes Therapeutics, Inc. · 2017-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Capital Expenditure: 7551000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7551000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#204777 Filing: 000156459019005838 The citation records this snapshot. The page link may show a newer release later.	−USD 92.12 million Calculation and evidence -84565000 − 7551000 USD Exact free cash flow: -92116000 USD 2017-01-01 – 2017-12-31: -84565000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 7551000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Audentes Therapeutics, Inc. · 2017-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Free cash flow: -92116000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -84565000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#204142 Filing: 000156459019005838 Input fundies:CapitalExpenditure: 7551000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#204777 Filing: 000156459019005838 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 128.82 million Exact value Exact value: -128821000 USD 2018-01-01 – 2018-12-31: -128821000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Audentes Therapeutics, Inc. · 2018-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Net Income: -128821000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -128821000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#176116 Filing: 000156459019005838 The citation records this snapshot. The page link may show a newer release later.	−USD 107.98 million Exact value Exact value: -107978000 USD 2018-01-01 – 2018-12-31: -107978000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Audentes Therapeutics, Inc. · 2018-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Operating Cash Flow: -107978000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -107978000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#203929 Filing: 000156459019005838 The citation records this snapshot. The page link may show a newer release later.	USD 11.61 million Exact value Exact value: 11609000 USD 2018-01-01 – 2018-12-31: 11609000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Audentes Therapeutics, Inc. · 2018-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Capital Expenditure: 11609000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11609000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#204566 Filing: 000156459019005838 The citation records this snapshot. The page link may show a newer release later.	−USD 119.59 million Calculation and evidence -107978000 − 11609000 USD Exact free cash flow: -119587000 USD 2018-01-01 – 2018-12-31: -107978000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 11609000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Audentes Therapeutics, Inc. · 2018-12-31 Audentes Therapeutics, Inc. (edgar:1628738) Free cash flow: -119587000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1628738?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -107978000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#203929 Filing: 000156459019005838 Input fundies:CapitalExpenditure: 11609000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1628738/000156459019005838/bold-20181231.xml#204566 Filing: 000156459019005838 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

134 filings · 872 latest values · 872 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001628738, 1628738, BOLD, edgar:1628738

Also known as AUDENTES THERAPEUTICS, INC., Audentes Therapeutics, Inc., Audentes Therapeutics, Inc.

Audentes Therapeutics, Inc.

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

Growth

Profit and cash

Balance sheet

Cash generation